Summary
In a phase II study, 42 patients with advanced soft-tissue sarcoma were treated with ifosfamide by 24-h infusion and mesna by 4-h IV bolus, repeated every 3 weeks. Ten patients received ifosfamide 5.0 g/m2, 20 had the dosage increased to 8.0 g/m2, and 12 received 8.0 g/m2 from the outset. Mesna was given in doses of 400 mg/m2 or 600 mg/m2. Of 40 patients evaluable for response, six (15%) achieved complete response and nine (23%) partial response. The overall response rate was 38%. The median duration of response was 11 months. Treatment was associated with falls in peripheral WBC and alopecia in all patients. Most experienced severe nausea and vomiting. In seven nephrotoxicity developed, and two of these died of renal failure. Renal tubular defects and cerebral effects also occured. Mesna largely prevented haemorrhagic cystitis. Ifosfamide offers a new alternative to previous chemotherapy for advanced soft-tissue sarcoma, but alterations in dose or method will be necessary to reduce toxicity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Allen LM, Creaven PJ, Nelson RL (1976) Studies on the human pharmacokinetics of isophosphamide (NSC-109724). Cancer Treat Rep 60: 451
Bramwell V, Mouridsen H, Somers R, van Oosterom A, Sylvester R, Thomas D, Markham D, Crowther D, Pinedo H (1982) The influence of scheduling and performance status (P.S.) on chemotherapy of advanced soft-tissue sarcoma with cyclophosphamide (CY), vincristine (V), adriamycin (A), and DTIC (DIC). Proc Am Soc Clin Oncol 1:23
Bremarer DN, McCormick JStC, Thomson JWW (1974) Clinical trial of isophosphamide (NSC-109724) — Results and side-effects. Cancer Chemother Rep 58:889
Bryant BM, Jarman M, Ford HT, Smith IE (1980) Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (Mesnum) in patients with advanced carcinoma. Lancet II: 657
Cox PJ (1979) Cyclophosphamide cystitis — Identification of acrolein as the causative factor. Biochem Pharmacol 28:2045
Drings P, Fritsch H (1972) Experiences with ifosfamide in high individual doses in metastasising solid tumours. Verh Dtsch Ges Inn Med 78:166
Hahn RG, Ahman DA, Bisel HF (1973) A phase II study of adriamycin (NSC 123127) therapy for metastatic or inoperable sarcoma. Cancer Chemother Rep 57:102
Hoefer-Janker H, Scheef W, Günther U, Hüls W, Vahlensieck W, Brühl P (1975) Results obtained with fractionated ifosfamide massive-dose treatment in generalized malignant tumours Med Welt 26:972
Ormstad K, Orrenius S, Lastbom T, Uehara N, Pohl J, Stekar J, Brock N (1983) Pharmacokinetics and metabolism of sodium 2-mercaptoethane-sulfonate in the rat. Cancer Res 43:333
Pinedo HM, Kenis Y (1977) Chemotherapy of advanced soft-tissue sarcomas in adults. Cancer Treat Rep 4:67
Ritter S, Schröder HJ (1977) Clinical experience with the cytostatic ifosfamide. Med Welt 28:1395
Scheef W, Klein HO, Brock N, Burkert H, Günther U, Hoefer-Janker H, Mitrenga D, Schnitker J, Voigtmann R (1979) Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: Preliminary results. Cancer Treat Rep 63:501
Schnitker J, Brock N, Burkert H, Fichtner E (1976) Evaluation of a cooperative clinical study of the cytostatic agent ifosfamide. Arzneim Forsch 26:1783
Van Dyk JJ, Falkson HC, Van Der Merwe AM, Falkson G (1972) Unexpected toxicity in patients treated with iphosphamide. Cancer Res 32:921
White DR, Cooper MR, Spurr CL (1975) A comparison of single and three-day dosage schedules of adriamycin in adult solid tumours. Proc Am Soc Clin Oncol 16:250
Wicart L (1976) Ifosfamide in the treament of solid tumours and their metastases. Nouv Press Med 5:996
World Health Organization (1979) WHO Handbook for reporting results of cancer treatment. WHO, Geneva (offset publication no. 48)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stuart-Harris, R.C., Harper, P.G., Parsons, C.A. et al. High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma. Cancer Chemother. Pharmacol. 11, 69–72 (1983). https://doi.org/10.1007/BF00254247
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00254247